Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 664 publications
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma.
Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025
Operative performance of RAPNO DIPG imaging criteria-a study from the International DIPG/DMG Registry.
Journal: Neuro-oncology practice
Published: August 15, 2025
Supercharged NK Cells as a Promising Therapeutic Strategy to Target and Eliminate Aggressive DIPG Tumors in Pediatric Patients.
Journal: Critical reviews in immunology
Published: July 31, 2025
Patterns of relapse in diffuse intrinsic pontine glioma after convection-enhanced delivery of 124I-omburtamab.
Journal: Neuro-oncology advances
Published: July 25, 2025
Managing diffuse intrinsic Pontine glioma (DIPG) through japan's pediatric home medical care (PHMC) system, originally designed for medically complex children.
Journal: BMC palliative care
Published: July 24, 2025
PNOC009: Convection-enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine glioma.
Journal: Neuro-oncology advances
Published: June 27, 2025
Erratum to: Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma.
Journal: Neuro-oncology
Published: June 09, 2025
BMI-1 Modulation and Trafficking During M Phase in Diffuse Intrinsic Pontine Glioma.
Journal: bioRxiv : the preprint server for biology
Published: June 06, 2025
Integrative Multi-Omics Analysis Identifies Nuclear Factor I as a Key Driver of Dysregulated Purine Metabolism in DIPG.
Journal: bioRxiv : the preprint server for biology
Published: June 06, 2025
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials.
Journal: Nature communications
Published: June 04, 2025
Novel (1H‑Pyrazol-4-ylamino)pyrimidine Derivatives as Wee1 Inhibitors for Treatment of Cancer.
Journal: ACS medicinal chemistry letters
Published: May 30, 2025
Last Updated: 10/31/2025